TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Botox vs. Baclofen for Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient, male or female subjects of any race, and at least 18 years of age. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 50mlU/ml for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study;~* Minimal 4-month history stable neurological disorder resulting focal upper limb muscle spasticity (wrist and/or elbow)~* Disability Assessment Scale (DAS) ≥ 2 for the principal therapeutic intervention target as chosen by Investigator and Subject (i.e., hygiene, dressing, pain and cosmesis).~* Subjects who are able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms.~Exclusion Criteria:~* Female subjects who are pregnant (positive urine pregnancy test) or who have an infant they are breast-feeding or who are of childbearing potential and are not practicing a reliable method of birth control.~* Severe contracture at the wrist or a history of tendon transfer in the study limb.~* Cast of study limb within four weeks of Visit 1.~* Profound atrophy of the muscles in the target area(s) of injection.~* Progressive neurological disorder (e.g., multiple sclerosis).~* Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis or any other disease that might interfere with neuromuscular function.~* Orthostatic hypotension or current use of alpha-2 adrenergic agonists (e.g. clonidine).~* Current anticoagulant therapy and INR \> 3.5~* Significantly impaired renal and/or hepatic function, in the opinion of the Investigator.~* Failure to meet prohibited concomitant medication criteria (Supplement I)~* Subjects planning inpatient surgery during the study.~* Any uncontrolled systemic disease.~* Allergy or sensitivity to any component of the study medication.~* Recent alcohol or drug abuse.~* History of poor cooperation, non-compliance with medical treatment, or unreliability.~* Subjects currently participating in an investigational drug study or who have participated in an investigational drug study within 30 days of the Baseline Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (above 18 years) scheduled for planned open or robot-assisted resection of gastric cancer.~Exclusion Criteria:~* Allergy towards; iodine, indocyanine green or shellfish~* Severe liver insufficiency~* Thyrotoxicosis~* Nephropathy requiring dialysis~* Pregnancy or lactation~* Legally incompetent for any reason~* Withdrawal of inclusion consent~* Disseminated disease or other that contraindicates curative surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICG patient (Type: EXPERIMENTAL): All patients included in the study will be injected with ICG (0.2 mg/kg bodyweight) to assess gastric perfusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gastric Emptying of Water in Obese Term Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non laboring, term (≥37 weeks) pregnant women~* Scheduled for elective cesarean section~* aged ≥ 18 years old~* American Society of Anesthesiology physical class 1-3~Exclusion Criteria:~* multigestational pregnancy~* diagnosed for delayed gastric emptying (GERD, gastrointestinal disease)~* diabetes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Non-obese women (Type: None): body mass index lower than 30 (kg/m\^2) at term
- Obese women (Type: None): body mass index equal or greater than 30 (kg/m\^2) at term

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sufficient endurance to participate in rehabilitation sessions.~* Medically Stable~* Age \>21 years.~* Inability to perform normal ankle coordinated gait components.~* Participants should be able to walk and keep balance without physical assistance from another person~Exclusion Criteria:~* Acute or progressive cardiac, renal, respiratory, neurological disorders or malignancy.~* Lower motor neuron damage or radiculopathy~* Allergy or contraindication to anesthesia, Versed, (or comparable substitute.~* Active implantable device (e.g. pacemaker, implantable cardiac defibrillator, neurostimulator, or drug infusion device.~* Pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): radio frequency-controlled (RF) Microstimulator (RFM) Gait System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An International Double Cohort Study to Compare Laparoscopic Ventral Rectopexy With Laparoscopic Resection Rectopexy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with an indication for Laparoscopic Resection Rectopexy\* for External Rectal Prolapse (Oxford Grade V)~Exclusion Criteria:~* Under 18 years of age~* Former rectosigmoid resection~* Former rectal prolapse surgery~* Rectosigmoid tumor~* Severe mental retardation~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 2 (Type: ACTIVE_COMPARATOR): Cohort 2 (two) will consist of 120 patients with an external rectal prolapse (Oxford Grade V)treated by Laparoscopic Resection Rectopexy (LRR). These patients will be included in the US centers involved in this study and treated by LRR.
- Cohort 1 (Type: ACTIVE_COMPARATOR): Cohort one will consist of 120 patients with an external rectal prolapse (Oxford Grade V) which will be treated with Laparoscopic Ventral Rectopexy. As this is the standard treatment in the European centers involved in this study these patients will be selected in the participating centers in the Netherlands, Belgium and England.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Improve Functioning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.~* Participants must meet moderate to severe DSM-5 criteria for OUD. While individuals may also meet criteria for use disorders of other substances (with the exception of alcohol or benzodiazepines), they must identify opioids as their primary substance of abuse.~* Participants must report chronic pain for at least the past three months and have a Brief Pain Inventory score.~* Participants must be receiving treatment through the STAR program.~Exclusion Criteria:~* Participants who are pregnant.~* Participants with a history of/or current psychotic disorder.~* Participants with a history of dementia or other cognitive impairment.~* Participants with active suicidal ideation, or a suicide attempt within the past 90 days will be excluded.~* Participants with contraindications to receiving rTMS (including a history of seizures, or any implanted metal above the neck).~* Those with unstable general medical conditions.~* Those who are currently using naltrexone or tramadol.~* Those with current alcohol or benzodiazepine use disorders due to increased risk of seizure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- rTMS (Type: EXPERIMENTAL): Participants will receive 18 sessions of active rTMS delivered at 120% rMT.
- Sham TMS (Type: PLACEBO_COMPARATOR): Participants will receive 18 sessions of sham rTMS delivered through an inactive coil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years.~* Cirrhotic liver demonstrated by typical liver dysmorphy on imaging and/or liver biopsy.~* HCC with at least one lesion measuring more than 1 cm in diameter with a single dynamic imaging technique (CT or MRI), showing intense arterial uptake followed by washout of contrast in the venous-delayed phases, or diagnosed by biopsy.~* Borderline resectable disease eligible for surgical resection or radiofrequency destruction.~* No extra-hepatic dissemination.~* ECOG Performance status \< 2.~* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~* Signed written informed consent (approved by an Independent Ethics Committee) obtained prior to any study specific baseline procedures.~Exclusion Criteria:~* Decompensated cirrhosis (Child Pugh B, C).~* Extra-hepatic tumour spread.~* Previous or concomitant malignancies within five years other than basal cell carcinoma of the skin.~* Pregnancy, lactation or refusal to use adequate contraceptive measures (hormonal or barrier method of birth control, abstinence).~* Pre-existing other hepatic disease (liver abscess, hepatic sarcoidosis or tuberculosis, sclerosing cholangitis, ...).~* Previous trans-arterial radioembolization (TARE).~* History of allergic reactions attributed to compounds of similar chemical or biologic composition of the administered materials.~* Bleeding diathesis, history of cardiovascular ischemic disease or cerebrovascular incident within the last six months.~* Major surgery within four weeks.~* Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Uncontrolled Diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preoperative aTARE (Type: EXPERIMENTAL): The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older who meet the clinical criteria for septic shock~   a. Presence of two or more of the following: i. A core temp ≥38C or ≤36C; ii. A heart rate ≥90 beats/min; iii. A respiratory rate ≥ 20 breaths/min or PaCO2 ≤32mmHg or use of mechanical ventilation for an acute process; iv. A white blood cell count ≥12000/ml or ≤4000/ml or immature neutrophils \> 10%.~   b. Presence of defined (or suspected) site of infection as show by at least one of the following criteria: i. An organism grown in blood or sterile site; ii. An abscess or portion of infected tissue; iii. Suspected infection despite culture growth by the attending physician. c. Infusion of vasopressors is required to maintain blood pressure~2. Vasopressor requirements~   a. Patients can be considered for study inclusion when his/her vasopressor requirements are as follows: i. Norepinephrine 0.04-0.25 mcg/kg/min (plus or minus vasopressin) OR phenylephrine 0.2-2 mcg/kg/min (plus or minus vasopressin) AND ii. Last measured lactate value was \< 4 mmol/L AND iii. The patient is on stable or decreasing doses of vasopressors for 8 hours or more. This 8 hour measurement will start at the maximum amount of vasopressor support within the range defined in i. above.~3. Serum albumin level \<2.5g/dl. The level must be drawn within the last 24 hours of Time=0.~Exclusion Criteria:~1. Patients \<18 years old~2. Albumin administration 24 hours prior to the time of enrollment (Time=0)~3. Prisoners~4. Terminal state~5. Known adverse reaction to albumin administration~6. Pregnancy~7. Pathological conditions in which albumin administration is clinically indicated (hepatic cirrhosis with ascites, hepatorenal syndrome, intestinal malabsorption syndrome, nephrotic syndrome, burns)~8. Patients with acute liver failure or cirrhosis~9. Patients on continuous renal replacement therapy~10. Patients who are morbidly obese ≥40kg/m2~11. Religious objection to the administration of human blood products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 25% Albumin (Type: EXPERIMENTAL): 25% albumin 75 grams IV over 1 hour once.
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% normal saline 200mL IV over 1 hour once.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Head-dOwn Position for ischEmic Stroke With Middle Cerebral Artery (HOPES)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age ≥18 years~2. acute ischemic stroke within 10 - 30 days of onset~3. neurological deficit: 6≤NIHSS≤16~4. Large artery atherosclerosis stroke based on TOAST criteria~5. The responsibility vessels were the middle cerebral artery or internal carotid artery, and the degree of stenosis was more than 50%.~6. first stroke onset or past stroke without obvious neurological deficit (mRS≤1)~7. fully understand and cooperate with the doctor's instructions.~8. the availability of informed consent;~Exclusion Criteria:~1. Hemorrhagic stroke or mixed stroke~2. Combining with severe organ dysfunction~3. Past hemorrhagic stroke~4. A history of stroke with severe sequelae~5. Planning revascularization in 3 months~6. Ischemic stroke due to surgical intervention~7. participating in other clinical trials within 3 months~8. Pregnant or lactating women~9. any inappropriate patients assessed by the researcher

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Head down position (Type: EXPERIMENTAL): head-down position treatment combined with conventional rehabilitation.
- Conventional Rehabilitation (Type: SHAM_COMPARATOR): Conventional rehabilitation treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Dutch Asymptomatic Mitral Regurgitation Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Asymptomatic~* Severe organic mitral valve regurgitation.~* Preserved left ventricular function (left ventricular ejection fraction \>60% and left ventricular end-systolic dimension ≤45 mm)~* The likelihood of MV repair should be more than 90% determined by the local heart team with a cardiologist and cardiothoracic surgeon~Exclusion Criteria:~* Pulmonary hypertension (\>50 mmHg at rest)~* Atrial fibrillation~* Physical inability as determined by the heart team to undergo surgery~* Other life-threatening morbidity~* Higher expected surgical risks in advance, according to the dedicated heart team~* Moderate to severe kidney disease (eGFR less than 30 mL/min)~* Flail leaflet together with a left ventricular end systolic diameter (LVESD) \>40 mm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Early mitral valve repair (Type: ACTIVE_COMPARATOR): Early mitral valve repair
- Watchful waiting (Type: ACTIVE_COMPARATOR): Watchful waiting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HBsAg positive and anti-HBs negative more than 6 months~* YMDD mutation (+)during lamivudine therapy~* Serum ALT more than two times upper normal value~Exclusion Criteria:~* HAV IgM Ab + and/or HCV Ab+ and/or HDV Ab and/or HIV Av+~* The sign of decompensated liver disease~* Pregnant or lactating woman~* The history of hemoglobinopathy, autoimmune hepatitis, alcoholic liver disease~* Hemoglobin less than 8 g/dL (male), 7.5g/dL (female) or neutrophil count less than 1500/mm3 or platelet count less than 50,000/mm3~* Serum creatinine more than 1.5 times upper normal limit value~* The sign of malignancy or suggestive of malignancy or the history of malignancy, the recurrence rate within 2 years of which is more than 20%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamivudine plus adefovir (Type: ACTIVE_COMPARATOR): None
- Clevudine plus adefovir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of post-allogeneic hematopoietic stem cell transplantation (HSCT) aGVHD at screening~* Evidence of engraftment post-transplant~* Diagnosis of high-risk aGVHD, per refined Minnesota high-risk aGVHD criteria during screening~* Initiation of treatment with systemic corticosteroids for aGVHD at a dose of prednisone ≥2 milligrams per kilograms per day (mg/kg/day) by orally (PO) or methylprednisolone ≥2 mg/kg/day intravenously (or equivalent) in divided doses at diagnosis and up to 3 days prior to or on the same day as initiation of GDC-8264 (Day 1), with no taper planned prior to Day 3~Exclusion Criteria:~* Evidence of relapsed, progressing, or persistent malignancy, or treatment for relapse after transplant, or requirement for rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse~* Prior receipt of more than one allogeneic HSCT~* Prior receipt of solid organ transplantation that are target organs for aGVHD (e.g., liver transplant)~* Prior systemic treatment for aGVHD, except for the standard of care corticosteroid treatment initiated as part of this trial~* Diagnosis of chronic GVHD or overlap syndrome~* Uncontrolled active infection (i.e., progressive symptoms related to infection despite treatment, or persistently positive blood cultures despite treatment, or any other evidence of severe sepsis)~* Severe organ dysfunction (e.g., acute liver failure, renal failure requiring dialysis, ventilator support, or vasopressor therapy)~* Initiation or planned use of a marketed small molecule (excluding corticosteroids) or biologic therapy as treatment for aGVHD from the start of screening through the treatment period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GDC-8264, 35 mg (Type: EXPERIMENTAL): Participants will receive oral GDC-8264, 35 milligrams (mg), once daily (QD) for 28 days.
- GDC-8264, 75 mg (Type: EXPERIMENTAL): Participants will receive oral GDC-8264, 75 mg, PO, QD for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy